At meeting on guardrails for gene editing of human embryos, some call for a dead end
By Megan Molteni,
Stat
| 03. 28. 2025
WASHINGTON — Keith Joung knows better than a lot of people what, exactly, it might require to prove to regulators and patients that CRISPR could be safely used to alter the genome of a human embryo. If, of course, society decided that was a good idea. Joung, an early pioneer of the gene-editing technology, was the first to show CRISPR could target and cut DNA inside an embryo — in zebrafish — back in 2013.
Not long after, his group was among the earliest to discover that CRISPR could get a bit sloppy — inadvertently slicing up unintended regions of the genome in all sorts of cells — complicating hopes it might be used to cure illnesses from cancer to muscular dystrophy. A pathologist by training, Joung has spent much of the intervening decade designing ever-more sensitive methods for detecting these so-called off-target effects and finding ways to minimize the chances they occur.
Such methods have, in the last two years, proved pivotal in the decisions by regulators to approve the first CRISPR-based medicine — an infusion of gene-edited blood...
Related Articles
By Blake Brittain, Reuters | 05.12.2025
The University of California and the University of Vienna on Monday convinced a U.S. appeals court to revive their bid for patent rights to groundbreaking CRISPR gene-editing technology created by their Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier.
The ...
By Megan Molteni, Stat | 05.13.2025
Leading trade organizations representing the makers of cell and gene therapies are calling for a 10-year international moratorium on the use of CRISPR and other DNA-editing tools to create genetically modified children, according to a draft of the declaration provided...
By Laura Ungar, Associated Press | 04.26.2025
Emily Kramer-Golinkoff can’t get enough oxygen with each breath. Advanced cystic fibrosis makes even simple things like walking or showering arduous and exhausting.
She has the most common fatal genetic disease in the U.S., which afflicts 40,000 Americans. But her...
Gray wolf by Jessica Eirich via Unsplash
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...